Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronic Acid in High Grade Osteosarcoma
NCT00691236Phase 3Unknown
- Sponsor
- Tata Memorial Hospital
- Start
- May 2008
- Primary completion
- May 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of zoledronic acid in osteosarcoma (OS) (3 arms), sponsored by Tata Memorial Hospital. Primary endpoints: Histological Response (Necrosis) at 2 years and Disease Free Interval at 2 years. Status: unknown.
02
Drugs
zoledronic acid
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on NCT00691236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00691236.